New Ebola Test Produces Results in Remote Areas
FRIDAY, Nov. 9, 2018 -- The U.S. Food and Drug Administration has approved emergency use of a new Ebola fingerstick test, which includes a reader that makes it possible to obtain results outside a laboratory.
The DPP Ebola Antigen System makes obtaining test results possible in remote areas with limited lab resources, such as those in African nations affected by Ebola outbreaks, the agency said Friday in a news release.
"The scourge of Ebola tragically demonstrates that we're a global community when it comes to public health protection. Infectious disease doesn't recognize nation states," said FDA Commissioner Dr. Scott Gottlieb.
The emergency declaration permitting the test's use was made in response to an Ebola outbreak in the central-African nation of the Congo, the FDA said.
The agency cautioned that test results shouldn't be the only criterion used to determine a patient's course of treatment. Medical professionals also should consider a patient's history, vital signs, symptoms and likelihood of exposure, the FDA said.
The test is produced by Chembio Diagnostic Systems, based in Medford, N.Y.
© 2020 HealthDay. All rights reserved.
Posted: November 2018
Read this next
WEDNESDAY, Oct. 21, 2020 -- Stroke patients have a higher risk of death if they're admitted to a rural hospital on the weekend, a new study finds. University of Georgia...
WEDNESDAY, Oct. 21, 2020 -- Scientists knew that dangerous T-cells lived in the pancreases of people with type 1 diabetes, but a new study shows they also take up residence in the...
WEDNESDAY, Oct. 21, 2020 -- A third surge of coronavirus cases now has a firm grip on the United States, with an average of 59,000 new infections being reported across the country...
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.